OTIC Otonomy Inc.

2.3
-0.04  -2%
Previous Close 2.34
Open 2.34
Price To Book 0.78
Market Cap 70449288
Shares 30,630,125
Volume 165,062
Short Ratio
Av. Daily Volume 109,448

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181160025
  2. 8-K - Current report 181159911
  3. EFFECT - Notice of Effectiveness 181082551
  4. CORRESP [Cover] - Correspondence
  5. UPLOAD [Cover] - SEC-generated letter

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated 1H 2019.
OTO-413
Hidden hearing loss
Phase 3 data released August 30 failed to meet primary and key secondary endpoints.
OTO-104 AVERTS-1
Meniere's disease
Phase 1/2 trial to be initiated 1H 2019.
OTO-313
Tinnitus
Additional Phase 3 trial data due 1H 2020.
OTIVIDEX
Ménière's disease
Phase 2 trial completed October 2016. Phase 3 trial planned.
OTIPRIO
Pediatric patients with acute otitis media with tympanostomy tubes (AOMT)
Phase 2 trial initiation announced January 19, 2017.
OTO-104
Prevention of hearing loss in cancer patients undergoing chemotherapy
Approved December 11, 2015
OTIPRIO (ciprofloxacin otic suspension)
Ear Tube Placement Surgery
Approval announced March 2, 2018.
OTIPRIO
Acute otitis externa

Latest News

  1. Is Otonomy Inc (NASDAQ:OTIC) Excessively Paying Its CEO?
  2. Otonomy to Participate in Piper Jaffray 30th Annual Healthcare Conference
  3. Report: Developing Opportunities within Control4, Nanometrics, Century Casinos, Steven Madden, Otonomy, and C&J Energy Services — Future Expectations, Projections Moving into 2018
  4. Otonomy Presents Data Highlighting Potential of OTO-413, an Otic Sustained-Exposure Formulation of BDNF, to Treat Hearing Loss
  5. Edited Transcript of OTIC earnings conference call or presentation 5-Nov-18 9:30pm GMT
  6. Otonomy: 3Q Earnings Snapshot
  7. Otonomy Reports Third Quarter 2018 Financial Results and Provides Corporate Update
  8. Otonomy to Report Third Quarter 2018 Financial Results and Provide Corporate Update
  9. Report: Exploring Fundamental Drivers Behind St. Joe, Emerge Energy Services LP, Resources Connection, FormFactor, Global Brass and Copper, and Otonomy — New Horizons, Emerging Trends, and Upcoming Developments
  10. Otonomy Announces OTIVIDEX™ Data Presentation at American Academy of Otolaryngology - Head and Neck Surgery Foundation Annual Meeting
  11. Otonomy to Present at Cantor Fitzgerald Global Healthcare Conference
  12. Oculis Elects Anthony Rosenberg and David A. Weber - Veterans of the Global Pharmaceutical and Eye-care Industries - to its Board of Directors
  13. Who Owns Otonomy Inc (NASDAQ:OTIC)?
  14. Are Options Traders Betting on a Big Move in Otonomy (OTIC) Stock?
  15. Otonomy (OTIC) Reports Q2 Loss, Misses Revenue Estimates
  16. Otonomy, Inc. to Host Earnings Call

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181160025
  2. 8-K - Current report 181159911
  3. EFFECT - Notice of Effectiveness 181082551
  4. CORRESP [Cover] - Correspondence
  5. UPLOAD [Cover] - SEC-generated letter
  6. S-3 - Registration statement under Securities Act of 1933 181063317
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 181001563
  8. 8-K - Current report 181001454
  9. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 18945994
  10. 8-K - Current report 18912069